Evaluation Primary Care Considerations for the Diagnosis and Management of Migraine: Novel Strategies for the Treatment of Episodic Migraine Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe strategies to minimize the burden and suboptimal diagnosis/management of migraine in primary care settings, particularly among traditionally underserved populations 5 4 3 2 1 Assess the role of CGRP in the pathophysiology of migraine 5 4 3 2 1 Evaluate the role of CGRP receptor antagonists in the acute treatment of migraine and the preventive treatment of episodic migraine 5 4 3 2 1 Implement personalized treatment plans for episodic migraine across diverse patient populations for the provision of optimal care and outcomes 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Linda Davis, MD 5 4 3 2 1 Paul G. Mathew, MD, DNBPAS, FAAN, FAHS 5 4 3 2 1 Shirley Kessel 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with episodic migraines do you see during a typical month? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No In the United States, Hispanic patients with headaches are _____ less likely to receive a migraine diagnosis compared to White patients with headaches. 20% 30% 40% 50% Which of the following is expressed in both the peripheral and central nervous systems, including the trigeminovascular pathways, and is elevated during migraine attacks? Calcitonin gene-related peptide (CGRP) Formyl peptide receptor (FPR) Glucagon-like peptide (GLP) Relaxin family peptide receptor (RXFP) Which of the following is an intranasal formulation for the acute treatment of migraine in adults that received FDA approval based on statistically superior results of pain freedom and freedom from the most bothersome symptom at two hours post-dose? Atogepant Rimegepant Ubrogepant Zavegepant Which of the following is an oral medication indicated for both the acute treatment of migraine and prevention of episodic migraine in adults? Atogepant Rimegepant Ubrogepant Zavegepant How confident are you now in your ability to implement recent data, newer therapeutic strategies, and guideline-directed care in clinical practice to minimize episodic migraine risk and improve patient outcomes? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Utilize CGRP receptor antagonists for the acute treatment of migraine and/or prevention of episodic migraine Inquire about headache symptoms in patients Remain apprised of strategies to accurately screen/diagnose episodic migraine Consider healthcare disparities and impacts on special populations when managing patients with migraine Recommend alternative pharmacologic treatment options when a patient does not achieve remission on their current treatment regimen Remain apprised of the role of CGRP in the pathophysiology of migraine Remain apprised of clinical data associated with newer CGRP receptor antagonists for the treatment of migraine Implement personalized treatment plans for episodic migraine across diverse patient populations Other (please specify): Previous